Biotech

Auristone raises $4M seed to build solutions based on the science of your genes

April 5, 2024

It’s in the genes. Meet Auristone! This Singapore-founded biotech startup powers personalized healthcare solutions based on the science of how genes work (aka,  epigenomics).

Now, they’ve just raised a $4M seed!

Investor check. Elev8 led the round. SEEDS Capital joined in, along with existing investor Genedant.

👩🏻‍⚕️ Doctor, doctor!

Their first product, EPI-CALL helps doctors and late-stage cancer patients get clinical insights and figure out the best therapy options.

  • It’s a molecular profiling test that helps predict someone’s likelihood of response to different treatment options for cancer.
  • It works on top of the genomic information offered by existing providers.

They also offer other products:

  • Signomax: RNA Sequencing and Chromatin Immunoprecipitation Sequencing to support research efforts.
  • EPI-Tome: a novel biomarker and drug discovery engine driven by epigenomics.

💰 Money matters

They’ll be pushing for more clinical collaborations and market adoption for EPI-CALL.

Oh, and watch out, because they’ll be expanding to South Korea, Japan, and other markets too.

Know Southeast Asian tech in minutes.

The newsletter that keeps you up-to-date on the top stories on tech and business in Southeast Asia. It's fun, quick and free.
You're now subscribed to BackScoop. See you in your inbox!
Oops! Something went wrong while submitting the form.

Know Southeast Asian tech in minutes.

The newsletter that keeps you up-to-date on the top stories on tech and business in Southeast Asia. It's fun, quick and free.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.